Nano- or submicron-sized liposomes as carriers for drug delivery

Chang Gung Medical Journal

Volumn 29, Issue 4, 2006, Pages 358-362

  Fang, Jia You ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Drug delivery; Liposomes; Niosomes; Skin; Tumor

Indexed keywords

ALCOHOL; ANIONIC SURFACTANT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG CARRIER; DRUG VEHICLE; LIPOSOME; MACROGOL 2000; PACLITAXEL; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CONFOCAL LASER MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG TARGETING; ELECTRON SPIN RESONANCE; HUMAN; KAPOSI SARCOMA; OVARY CANCER; PHOSPHOLIPID BILAYER; SKIN FUNCTION; SKIN TEMPERATURE; STRATUM CORNEUM;

ADMINISTRATION, TOPICAL; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOSTRUCTURES;

EID: 33749478137     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 1976;295:704-10.
2. Honeywell-Nguyen PL, de Graaff AM, Groenink HW, Bouwstra JA. The in vivo and in vitro interactions of elastic and rigid vesicles with human skin. Biochim Biophys Acta 2002;1573:130-40.
3. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz, M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000;65:403-18.
4. Harashima H, Kiwada H. The pharmacokinetics of liposomes in tumor targeting. Adv Drug Deliv Rev 1999;40:1-2.
5. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005;1:47-64.
6. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
7. Kirjavainen M, Monkkonen J, Saukkosaari M, Valjakka-Koskela R, Kiesvaara J, Urtti A. Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J Control Release 1999;58:207-14.
8. Valenta C, Wanka M, Heidlas J. Evaluation of novel soyalecithin formulations for dermal use containing ketoprofen as a model drug. J Control Release 2000;63:165-73.
9. Fujii M, Shiozawa K, Watanabe Y, Matsumoto M. Effect of phosphatidylcholine on skin permeation of indomethacin from gel prepared with liquid paraffin and hydrogenated phospholipid. Int J Pharm 2001;222:57-64.
10. Valjakka-Koskela R, Kirjavainen M, Monkkonen J, Urtti A, Kiesvaara J. Enhancement of percutaneous absorption of naproxen by phospholipids. Int J Pharm 1998;175:225-30.
11. Ho NFH, Ganesan MG, Weiner ND, Flynn GL. Mechanisms of topical delivery of liposomally entrapped drugs. J Control Release 1985;2:61-5.
12. Lasch J, Laub R, Wohlrab W. How deep do intact liposomes penetrate into human skin? J Control Release 1991;18:55-8.
13. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003;42:1-36.
14. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995;16:285-94.
15. Harrington KJ, Syrigos KN, Vile RG. Liposomally targeted cytotoxic drugs for the treatment of cancer. J Pharm Pharmacol 2002;54:1573-600.
16. Allen TM, Hansen CB, Lopes de Menezes DE. Pharmacokinetics of long-circulating liposomes. Adv Drug Deliv Rev 1995;16:267-84.
17. Gabizon AA, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet 2003;42:419-36.
18. Wang JP, Maitani Y, Takayama K, Nagai T. Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposomes. Pharm Res 2000;17:782-7.
19. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999;40:89-102.
20. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62.
21. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.